Tenaya Therapeutics, Inc. (TNYA)
Health Care · Genetic medicines / cardiac gene therapy · NASDAQ
Tenaya Therapeutics is a clinical-stage biopharmaceutical company leveraging gene therapy and small molecule platforms to develop curative, precision-medicine treatments for genetically defined heart diseases.
What Tenaya Therapeutics, Inc. does
Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering precision medicine therapies that address the underlying genetic causes of heart disease. The company is advancing three clinical-stage candidates: TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy; TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy; and TN-301, a small molecule HDAC6 inhibitor for heart failure and other cardiac conditions. Tenaya combines proprietary drug discovery capabilities anchored in human genetics with internal expertise in AAV gene therapy development and manufacturing.
Themes: Gene therapy / genetic medicines, Precision medicine / genetic heart disease, Hypertrophic cardiomyopathy (HCM), Arrhythmogenic right ventricular cardiomyopathy (ARVC), Heart failure with preserved ejection fraction (HFpEF), Duchenne muscular dystrophy (DMD), Pulmonary arterial hypertension (PAH)
Fundamentals
- Price$0.6962 as of 2026-08-26 close
- Market cap$156M as of 2026-08-26
- 1-year return-35.5% 2025-08-26 close $1.08 → 2026-08-26 close $0.6962
- P/En/a earnings data not available
- ROE-108.0% as of 2026-08-26
- Debt / equity0.00 as of 2026-08-26
- Beta1.74 as of 2026-08-26
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How TNYA compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-26
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Tenaya Therapeutics, Inc. looks technically
Tenaya Therapeutics, Inc. (TNYA) is trading 17.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 141 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 70.4% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 47% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 17.0% below its 200-day average, the long-term trend line — a long-term downtrend | -17.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $0.7605 | $0.7605 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $0.8388 | $0.8388 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 48 calendar days ago — the swings before that are what the structure reading is measured on | 48 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 0.947. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 141 trading days ago — a "death cross", a bearish long-term signal | 141 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend) | 10.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 42.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($0.657 to $0.789) — its "stochastic" reading is 30 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 29.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 27 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.35 | $2.35 |
|---|---|---|
| From the 52-week high | it is 70.4% below its 52-week high (its highest price of the past year) | -70.4% |
| Above the 52-week low | it is 30.9% above its 52-week low (its lowest price of the past year) | +30.9% |
| Below the 52-week high | it is 70.4% below its highest point of the past year | 70.4% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $32.00 (set on 2021-11-08) | $32.00 |
| Given back of the 52-week move | over the past year its closes ranged ($0.55 to $2.10), and it has recovered only a small part of its fall from last year’s high — 9% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.51 to $1.56. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 9.4% |
| From the all-time high | it is 97.8% below its all-time high | -97.8% |
| Nearest price level | it is trading 3.3% above a support level at $0.6735 — a price it turned at twice since 2026-01-20, most recently on 2026-06-11. Since 2024-08-26 it has 4 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.3% |
| All-time low | its lowest closing price on record is $0.36 (set on 2025-05-13) | $0.36 |
| Above the all-time low | it is 93.4% above its all-time low | +93.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move | 6th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0422 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0422 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.67 and $0.78 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.67 – $0.72 – $0.78 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges below its 200-day average price (17.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 47% of its 30-day average | 0.47× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-26 1.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.0% |
|---|---|---|
| Open gap | it gapped 3.3% below the previous close 28 sessions ago and has not traded back through the level it left behind at 0.84 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.3% |
| Gap filled | a 2.3% gap up opened on 2026-08-19 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 13.8 percentage points (the stock lost 10.2% while the market gained 3.7%) | -13.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.0 percentage points (the stock lost 11.0% while the market gained 2.1%) | -13.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 3.2 percentage points (the stock gained 14.3% while the market gained 11.1%) | +3.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 54.3 percentage points (the stock lost 35.5% while the market gained 18.7%) | -54.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: outperforming the market over 6 months — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 10.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -16.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 11% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $0.7845 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -11.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $0.7209 — a volume-weighted average of daily closes over 16 sessions, not a true tick-by-tick VWAP. | -3.4% |
Price levels it has turned at before
TNYA last closed at $0.6962 on 2026-08-26. Since 2024-08-26 it has turned at 4 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.6735 | Support | 3.3% below the last close | turned there twice · 2026-01-20 to 2026-06-11 |
| $0.654 | Support | 6.1% below the last close | turned there three times · 2025-12-23 to 2026-04-29 |
| $0.7453 | Resistance | 7.0% above the last close | turned there three times · 2025-03-14 to 2026-05-19 |
| $0.817 | Resistance | 17.4% above the last close | turned there three times · 2026-01-07 to 2026-08-05 |
| $0.5342 | Support | 23.3% below the last close | turned there three times · 2025-04-25 to 2026-03-03 |
| $0.9457 | Resistance | 35.8% above the last close | turned there four times · 2025-07-21 to 2026-07-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $0.947.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $0.5053 and $0.674 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $0.947.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.29 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$3.20 range $2.00 – $5.00; median $3.00
Analyst estimates, as of 2026-08-25. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TNYA
- Consensus EPS estimate-$0.096 next reporting period, as of 2026-08-25
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Gene therapy candidates TN-201 and TN-401 are in early Phase 1b/2 clinical testing; there is no guarantee of positive efficacy or safety data or regulatory approval","Dependence on third parties for preclinical and clinical trial execution and manufacturing of product candidates","Significant intellectual property risk; protection scope and patent term extensions for cardiovascular genetic medicines remain uncertain, and third-party IP infringement claims could impede product development"]
What changed in the latest 10-Q
AI-assisted comparison of TNYA's 10-Q filed 2026-05-06 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to audited financial statements for year ended December 31, 2025 filed March 11, 2026 (newer filing), versus year ended December 31, 2024 filed March 10, 2025 (older filing)
- Statement that company 'has generated any revenue to date' removed and replaced with broader strategic language in Overview section
- Explicit mention of March 2026 multi-target research collaboration with Alnylam Pharmaceuticals for gene targets in cardiovascular disease
- Statement that Alnylam agreement 'provides reimbursement for research efforts'
- Clarification that for rare conditions the company strategy is to 'develop, manufacture and commercialize at least some of these programs on our own'
- Reference to TN-301 having 'potentially broad utility' in multiple disease areas including DMD, genetic DCM, and PAH (in addition to HFpEF)
- Phrase 'A per protocol review by the independent data safety monitoring board (DSMB) of all available data from the first six patients dosed determined that TN-201 had an acceptable safety profile to proceed'
- Statement 'We are enrolling additional patients in MyPEAK-1 to further characterize dose response and inform dose selection for late-stage clinical trials'
- Removed:
- Phrase 'Our vision is to change the treatment paradigm for heart disease, and in doing so improve and extend the lives of millions of patients' replaced with longer contextual passage
- Statement 'We are advancing a deep and diverse modality agnostic pipeline of targeted therapies for heart conditions discovered internally using our extensive target identification and validation and genetic medicine design and manufacturing capabilities'
- Phrase 'All of our programs are currently in the clinical or preclinical stage; we do not have any products approved for sale'
- Reference to 'Phase 1b/2a' clinical trial (changed to 'Phase 1b/2' in newer)
- Phrase 'In summer 2025, the independent data safety monitoring board (DSMB) for the MyPEAK-1 trial reviewed all available safety data from the first six patients dosed with TN-201'
- Statement 'We have since dosed one additional patient at the 6E13 vg/kg dose level with no new meaningful safety events associated with TN-201'
- Reference to 'Late-Breaking Science: Main Event session' at AHA Scientific Sessions 2025
- Statement 'Biopsy data demonstrated that TN-201 transduction and mRNA expression were robust'
- Phrasing 'DNA and RNA analyses of all three patients in Cohort 1 show evidence' changed to 'of cardiac biopsy samples from all three patients'
- Statement 'MyBP-C protein levels also increased over time across all patients in both cohorts for whom serial biopsies were available' (narrowed in newer version)
- Phrasing 'Of note, Patient 6 had a greater than 2-fold increase in cardiac transduction and expression at Week 12 relative to the averages' (reorganized in newer)
- Reworded:
- Overview section restructured: older version had separate paragraphs on capabilities and pipeline; newer version integrates strategy discussion with candidate descriptions
- 'myosin binding protein (MyBP-C)' changed to 'myosin-binding protein C (MyBP-C)' (hyphenation and capitalization)
- 'recombinant adeno-associated virus serotype 9 (AAV9) capsid' shortened to 'recombinant AAV9 capsid'
- TN-301 description expanded from single indication (HFpEF) to multiple indications with phrase 'potentially broad utility'
- Trial description: 'Phase 1b/2a' changed to 'Phase 1b/2'
- DSMB review timing: 'In summer 2025' changed to 'A per protocol review' with different framing of the decision process
- Patient 6 biopsy data reorganized: statement about 2-fold increase moved within narrative and connected to dose response observation
- MyBP-C protein level findings rephrased: older stated 'increased over time across all patients in both cohorts for whom serial biopsies were available'; newer specifies Cohort 1 average increase with clearer dose comparison to Patient 6
- Notes:
- Newer filing text appears truncated at end ('All patients with greater than 26 weeks of follow-up demonstrated impr'); older filing similarly truncated ('Two out of three Cohort 1 patients saw r'); full section comparison not possible
- Comparison limited to available text; complete MD&A sections may contain additional changes not visible in provided excerpts
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 8 sells ($21048) — 2 selling insiders
- Last 90 days0 buys · 8 sells ($21048) — 2 selling insiders
- Last 180 days0 buys · 11 sells ($27392) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-17. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TNYA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding TNYA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,504,745
- Reported value $8,658,284
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
TNYA had 21,987,556 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
TNYA had 9.81% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.74 days to cover at the same settlement.
- Reported short interest (shares) 21,987,556
- Short interest (% of shares outstanding) 9.81%
- Prior settlement (shares) 24,919,430
- Reported change -11.77%
- Days to cover (reported) 13.74
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alnylam Pharmaceuticals (ALNY)
- Rocket Pharmaceuticals (RCKT)
- MyoKardia (acquired by Bristol Myers Squibb)
- Cytokinetics (CYTK)
- BridgeBio Pharma (BBIO)
- Regenxbio (RGNX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TNYA vs…
Frequently asked questions
What does Tenaya Therapeutics, Inc. (TNYA) do?
Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering precision medicine therapies that address the underlying genetic causes of heart disease. The company is advancing three clinical-stage candidates: TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy; TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy;
What sector is Tenaya Therapeutics, Inc. (TNYA) in?
Tenaya Therapeutics, Inc. (TNYA) is classified in the Health Care sector. Its industry is Genetic medicines / cardiac gene therapy. It trades on NASDAQ.
Who are Tenaya Therapeutics, Inc.'s (TNYA) competitors?
Notable peers of Tenaya Therapeutics, Inc. (TNYA) include Alnylam Pharmaceuticals, Rocket Pharmaceuticals, MyoKardia (acquired by Bristol Myers Squibb), Cytokinetics and BridgeBio Pharma. This peer set is informational only — not financial advice.
Is Tenaya Therapeutics, Inc. (TNYA) overbought or oversold right now?
Tenaya Therapeutics, Inc. (TNYA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TNYA come from?
Fundamentals and prices come from market data, as of 2026-08-26; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.